Cancer stem cells (CSCs) refer to a certain subpopulation within the tumor entity that is characterized by restricted cellular proliferation and multipotent differentiation potency. The existence of CSCs has been proven to contribute to the heterogeneity of malignancies, accounting for intensified tumorigenesis, treatment resistance, and metastatic spread. Dormancy was proposed as a reversible state of cancer cells that are temporarily arrested in the cell cycle, possessing several hallmarks that facilitate their survival within a devastating niche. This transient period is evoked to enter an actively proliferating state by multiple regulatory alterations, and one of the most significant and complex factors comes from local and systemic inflammatory reactions and immune components. Although CSCs and dormant cancer cells share several similarities, the clear relationship between these two concepts remains unclear. Thus, the detailed mechanism of immune cells interacting with CSCs and dormant cancer cells also warrants elucidation for prevention of cancer relapse and metastasis. In this review, we summarize recent findings and prospective studies on CSCs and cancer dormancy to conclude the relationship between these two concepts. Furthermore, we aim to outline the mechanism of immune components in interfering with CSCs and dormant cancer cells to provide a theoretical basis for the prevention of relapse and metastasis.
Bone marrow mesenchymal stem cell (BMMSC) is one of the ideal seed cells in stem cell‐based regenerative medicine such as the myocardial infarction repairing; however, most of the infused BMMSCs would expire within 48h post cell transplantation. To further explore the mechanism involved in regulating the life span of BMMSC itself would be beneficial to understand the stem cell‐based regenerative medicine. Pim1 is one of the serine/threonine kinases involved in cell growth, however, little is known about the role of Pim1 in the proliferation of BMMSC. Here, Immunoblot and quantitative RT‐PCR revealed that Pim1 was decreased in SD rat BMMSCs induced by TGF¦Â1 (5 ng/ml) for 7 days while compared with the cells in the undifferentiated status. Treatment the cells with Pim1 inhibitor, quercetagetin (5.5 ¦ÌM), led to Pim1 changes in its activity but not expression; Transduction the cells with Pim1 shRNA resulted in obvious decrease of Pim1 expression and activity. Treatment with both the quercetagetin and Pim1 shRNA led to significant decrease in cell viability and cell numbers in day 7, and the proportion of G0/G1 in cell cycles also increased after such treatment for 7 days. Thus, our results indicate that the maintenance of Pim1 expression in rat BMMSC, though in a low level, is crucial for cell proliferation. Our results support the rational that Pim1 may be as a potential molecular target in stem cell‐based regenerative medicine.